Amlodipine increases vitamin D levels more than valsartan in newly diagnosed hypertensive patients: Pointing to an additional effect on bone metabolism or a novel marker of inflammation?

Renal Failure

Volumn 35, Issue 5, 2013, Pages 691-696

  Ay, Seyit Ahmet ^a   Karaman, Murat ^a   Cakar, Mustafa ^a   Balta, Sevket ^a   Arslan, Erol ^a   Bulucu, Fatih ^a   Demirbas, Seref ^a   Celik, Turgay ^a   Naharci, Mehmet Ilkin ^a   Demirkol, Sait ^a   Kurt, Omer ^a   Bozoglu, Ergun ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Amlodipine; Hypertension; Inflammation; Valsartan; Vitamin D

Indexed keywords

AMLODIPINE; CALCIUM; MAGNESIUM; PARATHYROID HORMONE; PHOSPHORUS; THYROID HORMONE; VALSARTAN; VITAMIN D;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BONE METABOLISM; CALCIUM METABOLISM; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PHOSPHATE METABOLISM; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL; VITAMIN DEFICIENCY; VITAMIN METABOLISM;

ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BONE REMODELING; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES; VALINE; VITAMIN D;

EID: 84877842704     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2013.780976     Document Type: Article

References (21)

1. Cappuccio FP, Meilahn E, Zmuda JM, Cauley JA. High blood pressure and bone-mineral loss in elderly white women: A prospective study of Osteoporotic Fractures Research Group. Lancet. 1999;354(9183):971-975 (Pubitemid 29438401)
2. Shimizu H, NakagamiH, Yasumasa N, et al. Cilnidipine, but not amlodipine, ameliorates osteoporosis in ovariectomized hypertensive rats through inhibition of the N-Type calcium channel. Hyperten Res. 2012;35(1):77-81
3. Awad AB, Alappat L, Valerio M. Vitamin D and metabolic syndrome risk factors: Evidence and mechanisms. Crit Rev Food Sci Nutr. 2012;52(2):103-112
4. Unlu M, Karaman M, Ay SA, et al. The comparative effects of valsartan and amlodipine on vascular microinflammation in newly diagnosed hypertensive patients. Clin Exp Hypertens. 2012. [Epub ahead of print]. doi: 10.3109/10641963. 2012.739237
5. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502
6. Rejnmark L, Vestergaard P, Mosekilde L. Treatment with betablockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: A nationwide case-control study. J Hyperten. 2006;24(3):581-589 (Pubitemid 43261923)
7. Rejnmark L, Vestergaard P, Mosekilde L. Reduced fracture risk in users of thiazide diuretics. Calcif Tissue Int. 2005;76 (3):167-175 (Pubitemid 41557145)
8. McGreevy C, Williams D. New insights about vitamin D and cardiovascular disease: A narrative review. Ann Intern Med. 2011;155(12):820-826
9. Kota SK, Kota SK, Jammula S, et al. Renin-Angiotensin system activity in vitamin D deficient, obese individuals with hypertension: An urban Indian study. Indian J Endocrinol Metab. 2011;15(Suppl. 4):S395-S401
10. McCarron DA. Blood pressure and calcium balance in the Wistar-Kyoto rat. Life Sci. 1982;30(7-8):683-689 (Pubitemid 12151878)
11. Young EW, Bukoski RD, McCarron DA. Calcium metabolism in experimental hypertension. Proc Soc Exp Biol Med. 1988;187 (2):123-141 (Pubitemid 18077788)
12. Fukuda S, Tsuchikura S, Iida H, Ikeda K, Nara Y, Yamori Y. Intestinal calcium absorption and response of calcium regulating hormones in the stroke-prone spontaneously hypertensive rat as a model of osteoporosis. Clin Exp Pharmacol Physiol Suppl. 1995;22(1):S240-S241 (Pubitemid 26062090)
13. Yamori Y, Fukuda S, Tsuchikura S, Ikeda K, Nara Y, Horie R. Stroke-prone SHR (SHRSP) as a model for osteoporosis. Clin Exp Hyperten Part A. 1991;13(5):755-762
14. Tsuda K, Nishio I, Masuyama Y. Bone mineral density in women with essential hypertension. Am J Hypertens. 2001;14(7 Pt 1):704-707 (Pubitemid 32612537)
15. Ushijima K, Liu Y, Maekawa T, et al. Protective effect of amlodipine against osteoporosis in stroke-prone spontaneously hypertensive rats. Eur J Pharmacol. 2010;635(1-3):227-230
16. Vestergaard P, Rejnmark L, Mosekilde L. Hypertension is a risk factor for fractures. Calcif Tissue Int. 2009;84(2):103-111
17. Zicha J, Kunes J, Ben-Ishay D, Devynck MA. Abnormal regulation of cytosolic calcium and pH in platelets of Sabra rats in early phases of salt hypertension development. Can J Physiol Pharmacol. 1996;74(11):1222-1228 (Pubitemid 27079779)
18. Kanbay M, Isik B, Akcay A, et al. Relation between serum calcium, phosphate, parathyroid hormone and "nondipper" circadian blood pressure variability profile in patients with normal renal function. Am J Nephrol. 2007;27(5): 516-521 (Pubitemid 47482009)
19. HaliciZ,BorekciB,OzdemirY,CadirciE, SuleymanH. Protective effects of amlodipine and lacidipine on ovariectomy-induced bone loss in rats. Eur J Pharmacol. 2008;579(1-3):241-245
20. Gradosova I, Zivna H, Palicka V, Hubena S, Svejkovska K, Zivny P. Protective effect of amlodipine on rat bone tissue after orchidectomy. Pharmacology. 2012;89(1-2):37-43
21. Moraes RB, Corrêa L, Luz JGC. Adverse effects of the amlodipine on bone healing of the mandibular fracture: An experimental study in rats. Oral Maxillofac Surg. 2011;15 (2):93-101